Mesothelioma Therapy Immunotherapy and Targeted Therapy 1

Question 1

Which immunotherapy regimen received FDA approval for first-line treatment of unresectable pleural mesothelioma?

Accepted Answer

Nivolumab + ipilimumab

Answer

Nivolumab + ipilimumab (CheckMate 743) received FDA approval in 2020 as first-line treatment for unresectable pleural mesothelioma.

Question 2

Nivolumab is classified as which type of immunotherapy?

Accepted Answer

PD-1 checkpoint inhibitor

Answer

Nivolumab is a PD-1 checkpoint inhibitor that blocks the PD-1 receptor on T cells, restoring their ability to attack cancer cells.

Question 3

Ipilimumab targets which immune checkpoint?

Accepted Answer

CTLA-4

Answer

Ipilimumab is a CTLA-4 inhibitor that blocks this immune checkpoint, enhancing T-cell activation and anti-tumor immune responses.

Question 4

In the CheckMate 743 trial, nivolumab + ipilimumab showed the greatest benefit in which mesothelioma subgroup?

Accepted Answer

Non-epithelioid (sarcomatoid/biphasic) cell type

Answer

Non-epithelioid mesothelioma (sarcomatoid/biphasic types) showed the greatest benefit from nivolumab + ipilimumab compared to chemotherapy in CheckMate 743.

Question 5

What is a common immune-related adverse event (irAE) associated with checkpoint inhibitors in mesothelioma?

Accepted Answer

Colitis, pneumonitis, hepatitis, and endocrinopathies

Answer

Checkpoint inhibitors commonly cause immune-related adverse events including colitis, pneumonitis, hepatitis, and endocrinopathies due to T-cell overactivation.

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Immunotherapy and Targeted Therapy 1